MYC and hepatocellular carcinoma: In this case, we established an HDT-based HCC mouse model in C57BL/6JNarl mice with co-administration of NrasV12/MYC oncogenes either with MTA1 or MTA1dE4 to assess their additive effect in terms of promoting tumorigenesis.